Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-90
SponsorHospices Civils de Lyon

About this trial

This protocol describes a study aimed at evaluating the psychometric properties of the ExéSem battery, developed to differentiate semantic deficits from executive semantic impairments in patients with post-lesional or neurodegenerative anomia. Currently available tools do not allow a straightforward distinction between these deficits, limiting diagnostic accuracy and clinical management. The ExéSem battery was developed through a collaboration between Hospices Civils de Lyon, the University of Mons, and Laval University to address this gap.

The battery includes three main tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-picture matching task, and (3) a rapid naming task. Each task is designed to manipulate the level of executive control required to access semantic representations. This allows the identification of whether performance declines under increased executive demand, thereby distinguishing executive-related semantic impairments.

Eligibility criteria

Qualifiers

- Participants without cognitive impairment

Participant aged 50 to 90 years (inclusive);

Participant whose native language is French

Participant affiliated with or entitled to a social security scheme;

Disqualifiers

Severe, progressive, or unstable medical conditions that may interfere with assessment variables (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection);

Substance use that may affect cognitive performance;

Deafness or blindness that may compromise the participant's assessment or participation in tasks and scales;

Participants under guardianship, curatorship, or legal protection;

Trial design

Treatments tested in this trial

  • ExéSem cognitive battery

Treatment groups

140 Participants
are divided into 2 treatment groups

Sponsors and collaborators